Antinociceptive effects of [D-Ala2]deltorphin II, a highly selective δ agonist in vivo

Qi Jiang, Henry I. Mosberg, Frank Porreca

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The present study has characterized the antinociceptive actions of [D-Ala2]deltorphin II following intracerebroventricular (i.c.v.) administration in the mouse tail-flick test. [D-Ala2]deltorphin II produced dose- and time-related antinociception, with maximal effects at +10 min and significant antinociception which lasted for 40-60 min. [D-Ala2]deltorphin II was 13-fold more potent than i.c.v. [D-Pen2, D-Pen5]enkephalin (DPDPE), a second highly selective δ agonist, and approximately equipotent with i.c.v. morphine in producing antinociception. The antinociceptive effects of i.c.v. [D-Ala2]deltorphin II and DPDPE, but not those of morphine, were antagonized by the selective δ antagonist, ICI 174,864. In contrast, pretreatment with the non-equilibrium μ antagonist, β-funaltrexamine blocked morphine antinociception, but failed to antagonize [D-Ala2]deltorphin II and DPDPE antinociception. These data indicate that [D-Ala2]deltorphin II produced its antinociceptive effects at a supraspinal δ receptor. [D-Ala2]deltorphin II appears to be the most appropriate δ opioid agonist currently available for studies in vivo and support the involvement of δ receptors in supraspinal antinociception.

Original languageEnglish (US)
JournalLife Sciences
Volume47
Issue number11
DOIs
StatePublished - 1990

Fingerprint

D-Penicillamine (2,5)-Enkephalin
Morphine
Ala(2)-deltorphin II
Opioid Analgesics
Tail

ASJC Scopus subject areas

  • Pharmacology

Cite this

Antinociceptive effects of [D-Ala2]deltorphin II, a highly selective δ agonist in vivo. / Jiang, Qi; Mosberg, Henry I.; Porreca, Frank.

In: Life Sciences, Vol. 47, No. 11, 1990.

Research output: Contribution to journalArticle

@article{1ec5a959e7724e6c80fe887e9d1e6b58,
title = "Antinociceptive effects of [D-Ala2]deltorphin II, a highly selective δ agonist in vivo",
abstract = "The present study has characterized the antinociceptive actions of [D-Ala2]deltorphin II following intracerebroventricular (i.c.v.) administration in the mouse tail-flick test. [D-Ala2]deltorphin II produced dose- and time-related antinociception, with maximal effects at +10 min and significant antinociception which lasted for 40-60 min. [D-Ala2]deltorphin II was 13-fold more potent than i.c.v. [D-Pen2, D-Pen5]enkephalin (DPDPE), a second highly selective δ agonist, and approximately equipotent with i.c.v. morphine in producing antinociception. The antinociceptive effects of i.c.v. [D-Ala2]deltorphin II and DPDPE, but not those of morphine, were antagonized by the selective δ antagonist, ICI 174,864. In contrast, pretreatment with the non-equilibrium μ antagonist, β-funaltrexamine blocked morphine antinociception, but failed to antagonize [D-Ala2]deltorphin II and DPDPE antinociception. These data indicate that [D-Ala2]deltorphin II produced its antinociceptive effects at a supraspinal δ receptor. [D-Ala2]deltorphin II appears to be the most appropriate δ opioid agonist currently available for studies in vivo and support the involvement of δ receptors in supraspinal antinociception.",
author = "Qi Jiang and Mosberg, {Henry I.} and Frank Porreca",
year = "1990",
doi = "10.1016/0024-3205(90)90545-3",
language = "English (US)",
volume = "47",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Antinociceptive effects of [D-Ala2]deltorphin II, a highly selective δ agonist in vivo

AU - Jiang, Qi

AU - Mosberg, Henry I.

AU - Porreca, Frank

PY - 1990

Y1 - 1990

N2 - The present study has characterized the antinociceptive actions of [D-Ala2]deltorphin II following intracerebroventricular (i.c.v.) administration in the mouse tail-flick test. [D-Ala2]deltorphin II produced dose- and time-related antinociception, with maximal effects at +10 min and significant antinociception which lasted for 40-60 min. [D-Ala2]deltorphin II was 13-fold more potent than i.c.v. [D-Pen2, D-Pen5]enkephalin (DPDPE), a second highly selective δ agonist, and approximately equipotent with i.c.v. morphine in producing antinociception. The antinociceptive effects of i.c.v. [D-Ala2]deltorphin II and DPDPE, but not those of morphine, were antagonized by the selective δ antagonist, ICI 174,864. In contrast, pretreatment with the non-equilibrium μ antagonist, β-funaltrexamine blocked morphine antinociception, but failed to antagonize [D-Ala2]deltorphin II and DPDPE antinociception. These data indicate that [D-Ala2]deltorphin II produced its antinociceptive effects at a supraspinal δ receptor. [D-Ala2]deltorphin II appears to be the most appropriate δ opioid agonist currently available for studies in vivo and support the involvement of δ receptors in supraspinal antinociception.

AB - The present study has characterized the antinociceptive actions of [D-Ala2]deltorphin II following intracerebroventricular (i.c.v.) administration in the mouse tail-flick test. [D-Ala2]deltorphin II produced dose- and time-related antinociception, with maximal effects at +10 min and significant antinociception which lasted for 40-60 min. [D-Ala2]deltorphin II was 13-fold more potent than i.c.v. [D-Pen2, D-Pen5]enkephalin (DPDPE), a second highly selective δ agonist, and approximately equipotent with i.c.v. morphine in producing antinociception. The antinociceptive effects of i.c.v. [D-Ala2]deltorphin II and DPDPE, but not those of morphine, were antagonized by the selective δ antagonist, ICI 174,864. In contrast, pretreatment with the non-equilibrium μ antagonist, β-funaltrexamine blocked morphine antinociception, but failed to antagonize [D-Ala2]deltorphin II and DPDPE antinociception. These data indicate that [D-Ala2]deltorphin II produced its antinociceptive effects at a supraspinal δ receptor. [D-Ala2]deltorphin II appears to be the most appropriate δ opioid agonist currently available for studies in vivo and support the involvement of δ receptors in supraspinal antinociception.

UR - http://www.scopus.com/inward/record.url?scp=0025151599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025151599&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(90)90545-3

DO - 10.1016/0024-3205(90)90545-3

M3 - Article

VL - 47

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 11

ER -